Author(s): Schuessler A, Walker DG, Khanna R
Abstract Share this page
Abstract Glioblastoma multiforme (GBM) has a very poor prognosis, despite multimodal therapy including surgery, radiation and chemotherapy. A novel adoptive immunotherapy that exploits the presence of cytomegalovirus antigens in malignant brain cancer cells has been shown to be safe and elicit potential clinical benefit for the treatment of recurrent GBM.
This article was published in Oncoimmunology
and referenced in Journal of Carcinogenesis & Mutagenesis